• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Asthma: effect of excess short-acting β-agonist (SABA) inhaler prescriptions on healthcare resource utilisation.

作者信息

Levy Mark L, Capstick Toby Gd, Antalffy Thomas

机构信息

Kenton Bridge Medical Centre, Harrow.

Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds.

出版信息

Br J Gen Pract. 2024 Jul 25;74(745):374-376. doi: 10.3399/bjgp24X739089. Print 2024 Aug.

DOI:10.3399/bjgp24X739089
PMID:39054088
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11299697/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf91/11299697/bb61e2af441b/bjgpaug-2024-74-745-374.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf91/11299697/bb61e2af441b/bjgpaug-2024-74-745-374.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf91/11299697/bb61e2af441b/bjgpaug-2024-74-745-374.jpg

相似文献

1
Asthma: effect of excess short-acting β-agonist (SABA) inhaler prescriptions on healthcare resource utilisation.哮喘：短效β受体激动剂（SABA）吸入器处方过量对医疗资源利用的影响。
Br J Gen Pract. 2024 Jul 25;74(745):374-376. doi: 10.3399/bjgp24X739089. Print 2024 Aug.
2
Knowledge, practice pattern and attitude toward asthma management amongst physicians from Nepal, Malaysia, Lebanon, Myanmar and Morocco.尼泊尔、马来西亚、黎巴嫩、缅甸和摩洛哥的医生对哮喘管理的知识、实践模式和态度。
J Asthma. 2021 Jul;58(7):979-989. doi: 10.1080/02770903.2020.1742351. Epub 2020 Apr 17.
3
Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population.哮喘处方趋势、吸入器依从性和结果：多民族亚洲哮喘人群的真实世界数据分析。
NPJ Prim Care Respir Med. 2024 Nov 3;34(1):35. doi: 10.1038/s41533-024-00391-w.
4
SABA prescriptions and asthma management practices in Singapore: results from a cross-sectional, observational SABINA III study.新加坡的 SABA 处方和哮喘管理实践：来自 SABINA III 研究的一项横断面观察性研究结果。
BMJ Open. 2024 Jun 10;14(6):e064245. doi: 10.1136/bmjopen-2022-064245.
5
Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia.在澳大利亚，接受全科医生管理并开具固定剂量联合疗法的患者中哮喘和鼻炎控制不佳的情况。
J Asthma. 2018 Jun;55(6):684-694. doi: 10.1080/02770903.2017.1353611. Epub 2017 Sep 8.
6
Determination of asthma control using administrative data regarding short-acting beta-agonist inhaler purchase.利用短效β-激动剂吸入器购买的管理数据来确定哮喘控制情况。
J Asthma. 2018 May;55(5):571-577. doi: 10.1080/02770903.2017.1348513. Epub 2017 Aug 16.
7
Single inhaler combination inhaled corticosteroid-formoterol as both maintenance and reliever (SMART) compared with a step up of treatment with fixed-dose inhaled corticosteroid-long-acting β2-agonist maintenance with a short-acting β2-agonist as reliever in adolescents and adults with poorly controlled asthma in Colombia: a cost-utility analysis.在哥伦比亚，将单剂量吸入器联合吸入性糖皮质激素-福莫特罗作为维持和缓解药物（SMART）与逐步增加治疗方案（使用固定剂量吸入性糖皮质激素-长效β2受体激动剂维持治疗并使用短效β2受体激动剂作为缓解药物）用于哮喘控制不佳的青少年和成人的成本-效用分析。
J Asthma. 2025 Mar;62(3):500-507. doi: 10.1080/02770903.2024.2410424. Epub 2024 Oct 1.
8
Uncovering patterns of inhaler technique and reliever use: the value of objective, personalized data from a digital inhaler.揭示吸入器技术和缓解药物使用模式：数字化吸入器提供客观、个性化数据的价值。
NPJ Prim Care Respir Med. 2024 Aug 20;34(1):23. doi: 10.1038/s41533-024-00382-x.
9
Short-acting β-agonists (SABA) overuse in asthma and patients' perceptions for this behavior.短效β-激动剂（SABA）在哮喘中的过度使用和患者对此行为的认知。
Respir Med. 2024 Sep;231:107723. doi: 10.1016/j.rmed.2024.107723. Epub 2024 Jun 25.
10
SABINA + Hong Kong: a territory wide study of prescribing trends and outcomes associated with the use of short-acting β2 agonists in the Chinese population.沙巴林研究+香港：一项全港范围的研究，旨在调查与中国人群中使用短效β2 激动剂相关的处方趋势和结局。
BMC Pulm Med. 2024 May 14;24(1):232. doi: 10.1186/s12890-024-03038-1.

引用本文的文献

1
How to move towards more sustainable asthma care in Europe: an expert opinion paper.如何在欧洲实现更可持续的哮喘护理：一篇专家意见论文。
Breathe (Sheff). 2025 May 13;21(2):240229. doi: 10.1183/20734735.0229-2024. eCollection 2025 Apr.

本文引用的文献

1
A simple and effective evidence-based approach to asthma management: ICS-formoterol reliever therapy.一种简单有效的基于证据的哮喘管理方法：吸入性糖皮质激素-福莫特罗缓解治疗。
Br J Gen Pract. 2024 Jan 25;74(739):86-89. doi: 10.3399/bjgp24X736353. Print 2024 Feb.
2
Regular (up to 10 puffs 4-hourly) inhaled salbutamol should be prescribed at discharge after an asthma attack: myth or maxim?哮喘发作后出院时应常规（每4小时最多10喷）开具吸入沙丁胺醇处方：误区还是准则？
Breathe (Sheff). 2023 Sep;19(3):230054. doi: 10.1183/20734735.0054-2023. Epub 2023 Oct 10.
3
Healthcare costs associated with short-acting β-agonists in asthma: observational UK SABINA study.
哮喘中与短效β受体激动剂相关的医疗费用：英国SABINA观察性研究
BJGP Open. 2023 Sep 19;7(3). doi: 10.3399/BJGPO.2023.0015. Print 2023 Sep.
4
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update.2022 年全球哮喘倡议（GINA）更新：初级保健的主要建议。
NPJ Prim Care Respir Med. 2023 Feb 8;33(1):7. doi: 10.1038/s41533-023-00330-1.
5
The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review.ICS/福莫特罗缓解治疗方案在哮喘中的应用：综述。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):762-772.e1. doi: 10.1016/j.jaip.2023.01.002. Epub 2023 Jan 10.
6
Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America.短效β2-受体激动剂暴露与重度哮喘恶化：来自欧美 SABINA 研究的结果
J Allergy Clin Immunol Pract. 2022 Sep;10(9):2297-2309.e10. doi: 10.1016/j.jaip.2022.02.047. Epub 2022 Mar 29.
7
Overuse of short-acting β-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.哮喘患者过度使用短效β受体激动剂与急性加重风险及死亡率增加相关：全球SABINA项目的一项全国性队列研究
Eur Respir J. 2020 Apr 16;55(4). doi: 10.1183/13993003.01872-2019. Print 2020 Apr.
8
Asthma prescribing, ethnicity and risk of hospital admission: an analysis of 35,864 linked primary and secondary care records in East London.哮喘处方、种族与住院风险：对伦敦东部 35864 例初级和二级保健记录的分析。
NPJ Prim Care Respir Med. 2016 Aug 18;26:16049. doi: 10.1038/npjpcrm.2016.49.
9
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.哮喘患者超额死亡率及吸入性β受体激动剂使用情况的队列分析。
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):604-10. doi: 10.1164/ajrccm.149.3.8118625.
10
Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma.β受体激动剂使用增加模式与致命或近乎致命哮喘的风险
Eur Respir J. 1994 Sep;7(9):1602-9. doi: 10.1183/09031936.94.07091602.